Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Bronchogen peptide icon, one bubble per amino acidBronchogen4 residuesAEDLEach bubble = one amino acid. Size = residue mass. Color = chemical class.

Bronchogen

Beginner tier: 10 mg, daily · 4w on / 16w off · community consensus

~0.5-2 hours half-life (estimated)·Oral

Also known as: ADEL, Ala-Asp-Glu-Leu

Four amino acids long. That's the entire molecule. Bronchogen (AEDL) is a synthetic tetrapeptide bioregulator from Professor Vladimir Khavinson's research program in St. Petersburg, designed to target bronchial and pulmonary tissue at the gene expression level. Rat COPD models showed bronchial epithelial remodeling reversal after 30-day courses [1]. Zero human clinical trials exist, and all published data comes from a single research group. The oral capsule format (10 to 20 mg per day) makes it one of the few peptide bioregulators that doesn't require injection. A small but dedicated biohacker community follows the Khavinson cycling protocol for respiratory tissue support.

What Is Bronchogen?

Does a four-amino-acid chain actually reach bronchial tissue and change gene expression? That's the core question behind Bronchogen, also known by its sequence Ala-Glu-Asp-Leu (AEDL), a synthetic tetrapeptide from the Khavinson Institute of Bioregulation and Gerontology in St. Petersburg.

The proposed mechanism is direct DNA interaction. AEDL binds preferentially to CNG sequences in the major groove at N7 guanine positions, modulating transcription of genes tied to epithelial differentiation (NKX2-1, FOXA1, FOXA2), mucin production (MUC4, MUC5AC), and surfactant protein expression (SFTPA1). In vitro work confirmed the peptide increases DNA melting temperature by approximately 3.1 degrees Celsius [2].

The animal data is where things get interesting. Rat COPD models treated with month-long Bronchogen courses showed reversed bronchial epithelial remodeling, restored ciliated cell populations, normalized inflammatory cytokine profiles, and increased secretory IgA alongside surfactant protein B [1][3]. Those results came from Khavinson's group exclusively; no independent lab has replicated them.

Real-world use stays oral. The standard protocol is 10 to 20 mg per day in enteric-coated capsules for 20 to 30 days, repeated every 4 to 6 months. Fewer than 50 indexed community reports exist as of April 2026. Reddit has no dedicated Bronchogen threads. Users who do take it typically slot it into broader Khavinson longevity stacks alongside Epithalon and Thymalin. Most report no perceptible short-term effects, which actually matches the epigenetic model: benefits, if real, would emerge weeks to months after a completed course.

How Bronchogen Works

Khavinson's bioregulation model proposes that short peptides bypass cell-surface receptors entirely. Instead, AEDL penetrates cell nuclei and binds directly to DNA, distinguishing between methylated and unmethylated regions at CNG sequences.

The bronchial specificity comes from which genes the peptide accesses. In bronchial epithelial cells, AEDL binds promoter regions in the DNA major groove at N7 guanine positions. This interaction regulates transcription of epithelial differentiation factors including NKX2-1, SCGB1A1, FOXA1, and FOXA2. It also modulates mucin glycoprotein and surfactant protein expression. Downstream, the peptide shifts levels of Ki67 (proliferation), Mcl-1 (anti-apoptotic), p53 (tumor suppression), and NOS-3 (endothelial nitric oxide synthase). Effects are most pronounced in aged cell cultures [4].

Fluorescence-labeled peptide studies confirmed nuclear penetration of short peptides in this class [5]. In COPD rat models, the molecular cascade translated to measurable outcomes: reduced neutrophilic inflammation, restored epithelial barrier integrity, and recovery of secretory immune function through IgA upregulation [1].

One important caveat sits underneath all of this. Every mechanistic study traces back to a single research group. Independent replication of the DNA-binding model hasn't occurred in Western labs; the mechanism remains proposed rather than confirmed across multiple institutions.

Bronchogen Benefits

  • Bronchogen benefits center on bronchial tissue repair and respiratory gene regulation, based entirely on preclinical animal and in vitro data.
  • Rat COPD models showed full reversal of bronchial epithelial remodeling after 30-day courses, with restored ciliated cell populations in damaged airways [3].
  • Secretory IgA production increased in airway tissue, alongside surfactant protein B upregulation, both markers of restored mucosal immune defense [1].
  • DNA stabilization is measurable: AEDL raised DNA melting temperature by 3.1 degrees Celsius through major groove binding at N7 guanine [2].
  • Inflammatory cytokine profiles normalized in treated rat lung tissue, reducing neutrophilic inflammation without systemic immunosuppression.
  • The oral capsule format stands out among peptide bioregulators. Most peptides in this space require subcutaneous injection; Bronchogen's enteric-coated capsule is its practical advantage.
  • Gene expression changes regulated by Bronchogen include NKX2-1, FOXA1, FOXA2, MUC4, MUC5AC, and SFTPA1, covering epithelial differentiation, mucin production, and surfactant protein synthesis [4].

Bronchogen: Science vs Community Consensus

Partially Aligned
Scientific Evidence
Weak
Based on 5 key studies·Research only

All evidence is preclinical.

Dosing studied: 10–20 mg/day oral (capsule) for 20–30 day courses; no published injectable dosing protocol
Read the evidence (key study, limitations)

Rat COPD models [1][3] show bronchial epithelial remodeling reversal, ciliated cell restoration, IgA and surfactant protein B upregulation, and inflammatory cytokine normalization after month-long courses. In vitro: DNA stabilization (+3.1°C melting temperature) and tissue-specific gene expression modulation (NKX2-1, FOXA1/2, MUC4, MUC5AC, SFTPA1, Ki67, p53, NOS-3). No human RCTs published. All primary data originates from a single research group (Khavinson Institute, St. Petersburg). December 2024 MDPI study (Kononenko & Fedoreyeva) on ADEL in plant root development confirms DNA-interaction mechanism but has no clinical relevance.

Key Study

PMID 30199201: anti-inflammatory and regenerative effect of Bronchogen in obstructive lung pathology rat model (Khavinson group, 2018); PMID 26468022: modulating effect on bronchial epithelium in COPD rats (2015)

Limitations

Zero human RCTs; all data from one research group; oral bioavailability unpublished (~10–20% estimated); no independent replication of findings; Russian-language clinical documentation not indexed in English databases; publication bias from single-institute source cannot be excluded

Community Experience
Weak
3.0/5
Based on <50 indexed community reports as of April 2026

Niche bioregulator community only.

Community dosing: 10–20 mg/day oral (Khavinson protocol); 200–500 mcg/day SC injection (community injectable convention, undocumented)
Read the reports (what users report 4, common issues 4)

Near-zero Reddit presence (no dedicated threads on r/Peptides or r/longevity as of April 2026). Users follow Khavinson oral capsule protocols closely. A subset of US research-chemical community uses injectable form (lyophilized vial, SC), but dosing in this route has no published basis.

What users report (4)
  • Anecdotal easier breathing or subjective respiratory comfort during/after course
  • No injection required: oral format preferred for niche biohacker longevity stack
  • Reported carry-forward effect lasting weeks to months post-course per Khavinson model
  • Minimal perceived side effects: high tolerability anecdotally reported
Common issues (4)
  • No perceptible short-term effect in most users; efficacy unmeasurable without objective respiratory testing
  • Injectable dosing conventions have no published basis: wildly varying community recommendations (200 mcg to 5 mg/day SC)
  • Extremely limited community dataset: fewer than 50 indexed individual reports
  • Sourcing uncertainty: US research-grade lyophilized vials intended for research only, not equivalent to oral capsule format
Partially Aligned

Community oral protocols mirror Khavinson manufacturer specifications exactly: strong alignment on dose and cycling structure. Divergence exists on injectable route: community sources (200 mcg–5 mg/day SC) have no published basis and represent extrapolation from non-Bronchogen peptide practices. Evidence quality gap (community belief vs. absence of human data) is the core misalignment.

Bronchogen Dosage Guide

CommunityKhavinson Institute protocol
LevelDoseFrequency
Beginner10 mgDaily
Moderate20 mgDaily
Aggressive20 mgDaily
Note:

Bronchogen is oral, so there's no reconstitution math for the standard protocol. Take 1 to 2 enteric-coated capsules (10 to 20 mg each) on an empty stomach, 15 to 20 minutes before breakfast. Swallow whole with water. Don't crush or open them; the enteric coating protects the peptide from gastric acid proteolysis. Without it, the tetrapeptide gets digested before reaching the small intestine.

If you're using the injectable research vial route (no published basis, community convention only): reconstitute a 20 mg vial with 10 mL bacteriostatic water for a 2 mg/mL (2000 mcg/mL) concentration. At a 200 mcg dose, that's 10 units on a U-100 insulin syringe. At 500 mcg, that's 25 units.

The non-obvious thing most beginners miss: don't expect to feel anything during the course. The proposed mechanism is epigenetic. Any subjective benefits, if they exist, typically show up weeks to months after finishing a course. Repeating courses more often than every 4 months overlaps the residual effect window and adds cost without documented extra benefit.

Cycling Protocol

On Period
4 weeks
Off Period
16 weeks

Standard bioregulator protocol: 20-30 day oral course (1-2 capsules daily), repeated every 4-6 months. Some protocols suggest two consecutive courses with a 1-week break for initial loading.

Calculate your Bronchogen dose
Dosing tiers, timing, and cycle length

Or use the universal Peptide Calculator for any peptide.

Bronchogen Protocols by Goal

beginnerCommunity20 days on; 4–6 months off
Standard oral course
Wk ~3 (20 days)
10 mg/day (1 capsule) · Once daily · Oral

Expected: No subjective effects expected during the first week. Anecdotal respiratory comfort improvement occasionally reported by weeks 2–3. No validated human endpoints. Molecular effects (gene expression normalization) theorized to persist 3–6 months per Khavinson model.

Monitor: No mandatory labs: no validated biomarkers exist for Bronchogen in humans. Users tracking respiratory function may monitor SpO2 or spirometry (FEV1/FVC) before and 4–6 weeks post-course as an objective proxy.

How to Use Bronchogen

  1. 1
    Step 1

    Choose your dose: 10 mg (1 capsule) for a first course, 20 mg (2 capsules) for subsequent courses or the full Khavinson protocol.

  2. 2
    Step 2

    Take capsules on an empty stomach, 15 to 20 minutes before your first meal of the day. Morning dosing is preferred.

  3. 3
    Swallow whole with a small amount of water

    Do not crush, chew, or open the enteric-coated capsules. The coating is required for the peptide to survive gastric acid.

  4. 4
    Step 4

    Continue daily for 20 to 30 days (one full course).

  5. 5
    Step 5

    After completing the course, wait 4 to 6 months before repeating. Some protocols suggest two consecutive 10-day courses with a 1-week break for initial loading.

  6. 6
    Step 6

    Store capsules in original sealed packaging at 2 to 8 degrees Celsius, protected from light.

  7. 7
    Step 1

    Reconstitute a 20 mg lyophilized vial with 10 mL bacteriostatic water. This gives 2 mg/mL (2000 mcg/mL).

  8. 8
    Step 2

    Draw 10 units on a U-100 insulin syringe for a 200 mcg dose, or 25 units for 500 mcg.

  9. 9
    Step 3

    Inject subcutaneously in the abdominal area using a 29 to 31 gauge needle.

  10. 10
    Step 4

    Store reconstituted solution at 2 to 8 degrees Celsius and use within 24 hours per manufacturer guidance.

Oral Capsule Protocol (standard Khavinson route):

Injectable Research Route (community convention, no published data):

Alternative Routes

Oral enteric-coated capsule

10–20 mg/day (base dose per Khavinson protocol)

Standard route in the published Khavinson protocol. Enteric coating protects peptide from gastric acid; absorption occurs in small intestine. Oral bioavailability has never been measured; the 10 to 20 percent figure is an estimate. All preclinical studies citing oral administration used this route.

Subcutaneous injection (lyophilized research vial)

Community sources suggest 200–500 mcg/day SC (vs. oral 10–20 mg/day). The ~40–100× dose reduction vs. oral reflects assumed higher SC bioavailability extrapolated from other peptides: no Bronchogen-specific PK data confirms this.

US research-grade Bronchogen comes as lyophilized 20 mg vials for research reconstitution. Example reconstitution: add 10 mL bacteriostatic water to 20 mg vial → 2 mg/mL (2000 mcg/mL) solution. At 200 mcg dose → 10 units on U-100 insulin syringe. No safety or efficacy data for injectable route exists.

Bronchogen Stacking Protocols

Works With

Avoid

Systemic immunosuppressants (cyclosporine, tacrolimus, mycophenolate)

Bronchogen upregulates secretory IgA and modulates airway inflammatory cytokine profiles. Concurrent use with systemic immunosuppressants is unstudied and theoretically risks unpredictable immune dysregulation, particularly dangerous in transplant recipients.

Do not combine
High-dose systemic corticosteroids (oral/IV prednisolone, dexamethasone)

Both Bronchogen and systemic steroids affect airway inflammatory pathways (NOS-3, cytokine profiles). Theoretical combinatorial effect is unstudied. Moderate inhaled corticosteroids (ICS) at standard doses are not expected to interact.

Estimated Cost

Generic / Research
Oral capsules (Russian-source licensees): estimated $40–$80 per 60-cap box (exact 2026 pricing not confirmed). US research lyophilized vials (20 mg): estimated $45–$75/vial (exact current prices not confirmed in April 2026 search).

Pricing updated 2026-04-09

Bronchogen Side Effects

The biggest safety concern with Bronchogen isn't a specific adverse event. It's the absence of human safety data. Zero controlled clinical trials have been published. The entire published record comes from animal models, cell cultures, and molecular studies, all from a single institution. That means the side effect profile is incomplete by definition, not reassuring.

In the preclinical literature, month-long Bronchogen courses in rat COPD models produced no documented systemic toxicity or organ damage [1][3]. Animal tolerability looked clean. But animal tolerability doesn't guarantee human safety, particularly for a peptide whose proposed mechanism involves direct DNA interaction and gene expression modulation.

From the community side, the dataset is thin. Fewer than 50 indexed individual reports exist across forums, product review sections, and biohacker blogs. Within that small pool, oral Bronchogen is described as well tolerated. The most commonly mentioned complaint is mild gastrointestinal discomfort (bloating, mild nausea), typically occurring when capsules are taken with food rather than on an empty stomach 15 to 20 minutes before a meal. Adjusting timing resolves it for most users within 2 to 3 days.

Because Bronchogen is a fully synthetic tetrapeptide (four standard L-amino acids: alanine, glutamic acid, aspartic acid, leucine), prion contamination concerns that apply to animal-derived tissue extracts don't apply here. Allergic reactions to capsule excipients remain theoretically possible.

A separate risk category applies to the injectable route. Lyophilized research-grade Bronchogen vials (20 mg) are also sold in the US. A subset of users reconstitute these for subcutaneous injection at 200 to 500 mcg per day. No published pharmacokinetic, safety, or efficacy data supports injectable Bronchogen use at any dose. The community dosing conventions for SC administration are extrapolated from unrelated peptides. Injection-site reactions (redness, swelling, irritation) are possible with any subcutaneous peptide but haven't been systematically documented for Bronchogen specifically.

Drug interactions are unstudied. Theoretical caution applies to immunosuppressive medications (cyclosporine, tacrolimus, mycophenolate) because Bronchogen upregulates secretory IgA and modulates airway inflammatory cytokines. Combining it with systemic immunosuppressants could produce unpredictable immune effects. Standard inhaled corticosteroids at normal doses are not expected to interact. High-dose systemic corticosteroids (oral or IV prednisolone, dexamethasone) share overlapping inflammatory pathways (NOS-3, cytokine profiles) with Bronchogen, creating an unstudied theoretical interaction.

Bronchogen should not be used during pregnancy or breastfeeding (no safety data). Children under 18 lack pediatric dosing or safety data. Active acute respiratory infections (bronchitis, pneumonia) represent another contraindication due to insufficient data on use during acute illness.

Stop use and consult a physician if you experience allergic reactions (urticaria, significant GI distress), worsening respiratory symptoms, or fever during a course.

Common Issues & Solutions

Opening or crushing capsules: enteric coating is required to protect the peptide from gastric acid proteolysis; breaking the capsule likely renders the peptide inactive before reaching the small intestinal absorption site.

Expecting rapid subjective improvement: the proposed epigenetic mechanism is slow; no subjective benefit is expected in the first 7–10 days; the residual effect window (weeks post-course) is when anecdotal benefits are most commonly reported.

Using injectable community doses (200 mcg SC) without pharmacokinetic basis: SC dosing conventions for Bronchogen are extrapolated from non-Bronchogen peptides; no published PK or efficacy data supports any specific injectable dose for Bronchogen.

Repeating courses more often than every 4 months: the Khavinson epigenetic model proposes a 3–6 month residual effect; more frequent dosing overlaps the residual window and adds cost without documented incremental benefit.

Combining with Chonluten (Lys-Glu-Asp, a related bronchial cytogen) without data: both target bronchopulmonary tissue via proposed gene regulation; concurrent use is entirely unstudied. Note: Chonluten is not currently in the Peptide Schedule database.

Ask AI about this page

Ask AI for a second opinion on Bronchogen dosing and side effects

Contraindications

  • Pregnancy and breastfeeding (no safety data available)
  • Known hypersensitivity to any component of the peptide formulation
  • Children under 18 (no pediatric safety or dosing data)
  • Active acute respiratory infections (insufficient data on use during acute illness)

Drug Interactions

  • No formal drug interaction studies have been conducted
  • Theoretical caution with immunosuppressive medications due to IgA-modulating effects
  • May interact with other Khavinson bioregulator peptides: effects of combining multiple bioregulators are unstudied
  • No known interactions with standard bronchodilators or inhaled corticosteroids

Product Quality

Recommended Monitoring

TestWhenTarget
Spirometry (FEV1, FVC, FEV1/FVC ratio)Baseline before first course; 6 weeks post-course completionFEV1/FVC >0.70 (normal); any improvement in ratio or FEV1% predicted in previously impaired users is a positive signal
SpO2 (resting and post-mild-exertion)Daily during active course; weekly during residual effect window if trackingResting SpO2 ≥95%; post-exertion recovery to baseline within 2 minutes
Spirometry (FEV1, FVC, FEV1/FVC ratio)

Objective pulmonary function measure: the most practical biomarker for evaluating Bronchogen's proposed bronchial tissue effects in a self-experimenter context. Track trends across cycles.

SpO2 (resting and post-mild-exertion)

Simple non-invasive proxy for respiratory function; useful for trend tracking in users with known airway compromise. Not specific enough to confirm Bronchogen efficacy: use as supporting data only.

Bronchogen Before and After

Days 1-7

No noticeable effects expected. The peptide is beginning to interact with DNA in bronchial tissue and influence gene expression patterns at the molecular level.

Days 8-14

Subtle changes in gene expression and protein synthesis may be underway. Some users anecdotally report easier breathing, though this hasn't been validated in controlled studies.

Days 15-30

In animal models, measurable improvements in bronchial epithelium morphology and inflammatory markers are typically observed by the end of a 30-day course.

Weeks 5-16
post-course

Bioregulator effects are theorized to persist beyond the active dosing period due to sustained changes in gene expression patterns.

What to Expect

Days 1 to 7, Early molecular phase: The peptide absorbs through intestinal transporters (PepT1/LAT) and theoretically distributes to bronchial epithelial tissue. Animal model data suggests DNA interaction begins right away, but nothing measurable changes at the cellular level this early. You won't feel anything. Some users notice mild GI discomfort (bloating or nausea) if they take the capsule with food instead of before a meal; it clears up by day 2 or 3.

Days 8 to 20, Active course mid-phase: Per the Khavinson model, gene expression modulation continues: NKX2-1, FOXA1, and FOXA2 upregulation alongside inflammatory cytokine normalization and surfactant protein B increases. In animal models, histological improvements don't appear until the tail end of a 30-day course. Some users report subtle respiratory ease or reduced bronchial congestion starting around week 2. Not consistent across users, and no systematic data backs it up.

Days 20 to 30, Course completion: Rat COPD data shows measurable bronchial epithelial remodeling reversal, ciliated cell restoration, and secretory IgA upregulation by the end of a 30-day course. Human equivalence is unestablished. Most users finish the course without noticing anything dramatic. Any subjective respiratory improvement, when reported, tends to be mild.

1 to 6 months post-course, Residual effect window: This is actually where the Khavinson model says the real action happens. Gene expression changes are proposed to persist 3 to 6 months after the peptide clears. Cumulative benefit builds across multiple annual cycles, according to the theory. Community reports of subjective respiratory resilience, fewer bronchial irritation episodes, and sustained breathing ease cluster in this window. Without controlled studies, causal attribution isn't possible.

Detailed Timeline: Science vs Community

Days 1–7
Science

Short peptide absorption via intestinal transporters (PepT1/LAT); theoretical distribution to bronchial epithelial tissue. Animal model data suggests molecular-level DNA interaction begins immediately, but no measurable histological or functional change expected at this stage.

Community

Universally no perceptible effects. Occasional mild GI discomfort (bloating, nausea) if capsule taken with food rather than before a meal; resolves by day 2–3.

Days 8–20
Science

Continued gene expression modulation per Khavinson model (NKX2-1, FOXA1/2 upregulation; inflammatory cytokine normalization; surfactant protein B increase). Histological improvements in animal models emerge toward the end of month-long courses, not the first week.

Community

Some users anecdotally report subtle subjective respiratory ease or reduced bronchial congestion from week 2 onward. Not consistent across users. No systematic data.

Days 20–30
Science

Rat COPD model data shows measurable bronchial epithelial remodeling reversal, ciliated cell restoration, and secretory IgA upregulation by end of 30-day course. Human equivalence unestablished.

Community

Most users complete the course uneventfully. Any subjective respiratory improvement, when noted, is mild and inconsistent. No validated self-assessment endpoint without spirometry.

1–6 months post-course
Science

Khavinson epigenetic model proposes gene expression changes persist 3–6 months after peptide clearance. Cumulative benefit theorized to build across multiple annual cycles. No Bronchogen-specific RCT validates this timeline in humans.

Community

Attributed benefits most commonly reported in this window: subjective respiratory resilience, fewer episodes of bronchial irritation, sustained breathing ease. Impossible to attribute causally without controls.

Pharmacokinetics

Half-Life
1h
Bioavailability
Oral (enteric-coated): estimated 10-20%; SC: assumed higher but uncharacterized
Tmax
~30-60 minutes (estimated from tetrapeptide class)
Data Confidence
low

Source: Estimated from tetrapeptide class kinetics; no direct PK studies on Bronchogen published. Short-chain peptides of similar MW (~446 Da) typically have half-lives under 2 hours.

Pharmacokinetics: Active Dose Over Time

t½ = ~0.5-2 hours (estimated, tetrapeptide)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
4
Sequence
AEDL
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers
CAS: Unconfirmed (PubChem lists 857267-12-0 for Ala-Glu-Asp-Leu; sources disagree on the sequence)

Who Should Consider Bronchogen

  • Researchers studying bronchial epithelial gene regulation
  • Preclinical investigators exploring COPD peptide interventions
  • Individuals interested in Khavinson bioregulator protocols
  • Those researching age-related respiratory tissue changes

Related Peptides

What Changed for Bronchogen

No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

Peptide Schedule Research TeamReviewed Apr 7, 20265 Citations

References

  1. [1]Antiinflammatory and regenerative effect of peptide therapy in obstructive lung pathology (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]Modulating effect of peptide therapy on bronchial epithelium in rats with obstructive lung pathology (opens in a new tab)PubMed (opens in a new tab)PubMed
  4. [4]Peptide regulation of gene expression and protein synthesis in bronchial epithelium (opens in a new tab)PubMed (opens in a new tab)PubMed
  5. [5]Penetration of short fluorescence-labeled peptides into the nucleus and specific interaction with DNA (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Up to 2 years at 2-8°C in original sealed packaging, protected from light
After Reconstitution
Use within 24 hours if reconstituted; store at 2-8°C
Temperature
2-8°C (36-46°F)

Frequently Asked Questions

Bronchogen is a tetrapeptide (Ala-Glu-Asp-Leu) from the Khavinson bioregulator system. It is designed to target bronchial and lung tissue through short-peptide gene regulation. The proposed mechanism involves tissue-specific epigenetic modulation of respiratory epithelial cell gene expression. Clinical data is limited to Russian institutional studies.

Standard Khavinson protocol: 10-20 mg oral, daily for 10 consecutive days. Repeat 2-3 courses per year with 3-6 month rest periods between courses. The short-course approach is a core feature of the bioregulator model, based on the idea that brief peptide exposure triggers lasting epigenetic effects.

Published adverse effects are minimal in Russian clinical reports. Mild GI discomfort is occasionally reported. The tetrapeptide structure suggests low immunogenicity risk. Long-term safety data from controlled trials outside Russian institutions does not exist. The bioregulator class broadly has a favorable safety profile at standard doses.

No. Bronchogen has no FDA approval and no Western clinical trial data. All published research comes from Russian institutions, primarily the Saint Petersburg Institute of Bioregulation and Gerontology. Regulatory status is research-only in most jurisdictions outside Russia.

No. Bronchogen is taken by mouth and is not reconstituted with bacteriostatic water.